ArticleAfrican health sciences2026
Differences in anatomoclinical profiles between RAS-Mutated and Wild-Type colorectal cancers in an Eastern Algerian Cohort.
Article in African health sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Colorectal cancer (CRC) ranks as the third most prevalent malignancy globally, with incidence rates rising steadily in Algeria. Prognostic assessment of CRC increasingly relies on molecular profiling, particularly mutations in the KRAS gene a critical determinant of resistance to anti-EGFR therapies in metastatic disease. Objectives: This study investigates the KRAS mutational spectrum and its association with clinicopathological features in CRC patients from Batna, Eastern Algeria. Methods: In a retrospective analysis of 91 cases, KRAS mutations were identified in 46.2% of tumors (wild-type: 58.3%) using RT-PCR and sequencing. Results: The most frequent alterations localized to codons 12 and 13 (exons 1-2), with p.G12D (c.35G>A) and p.G13D (c.38G>A) predominating. Strikingly, KRAS mutation status showed no significant correlation with age, sex, tumor size, histology, metastatic pattern, or TNM stage suggesting its role as an independent molecular driver rather than a surrogate for conventional prognostic markers. Conclusion: These findings underscore the high prevalence of KRAS mutations in Algerian CRC patients and highlight their potential utility in refining therapeutic strategies, particularly for anti-EGFR eligibility. The study provides the first regional dataset from Eastern Algeria, addressing a critical gap in North African oncogenomics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.